PHVS · Pharvaris N.V.

This is a scheduled sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $34.68 to $35.11. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.

Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.84. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.10 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to 34.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to $34.98. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled sale from 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates.

This is a scheduled sale from 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.43 to $31.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on June 12, 2026. The shares were withheld on June 12, 2026 at a fair market value of $32.20 per share.

Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on June 11, 2026. The shares were withheld on June 11, 2026 at a fair market value of $31.51 per share.

The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $30.68 to $31.30 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.60 to $31.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $30.08 to $30.55 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The total number of shares beneficially owned previously reported in the Form 3 filed on March 18, 2026 was understated by 6,375 shares due to an administrative error in the number of shares reported as withheld for tax obligations in connection with an RSU vesting transaction. This filing reflects the corrected beneficial ownership amount.

The total number of shares beneficially owned previously reported in the Form 3 filed on March 18, 2026 was understated by 513 shares due to administrative errors in the number of shares reported as withheld for tax obligations in connection with RSU releases occurring on April 11, 2025 and March 12, 2026. This filing reflects the corrected beneficial ownership amount.

The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $30.08 to $30.49 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.60 to $30.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.